Drug Coated Balloon Angioplasty in Failing AV Fistulas: A Randomized Controlled Trial.

ABSTRACT:

Background

Restenosis remains a problem in hemodialysis access interventions. Paclitaxel-coated balloons have shown promise in reducing access-related restenosis in small trials. The primary hypotheses for our multicenter trial were superior effectiveness at 180 days and noninferior safety at 30 days of a drug-coated balloon compared with conventional angioplasty for treatment of dysfunctional arteriovenous fistulas.

Design, setting, participants, & measurements

This randomized trial enrolled 285 patients with dysfunctional arteriovenous fistulas at 23 centers. Grafts, central venous stenoses, thrombosed fistulas, and immature fistulas were excluded. All patients received angioplasty of the lesion responsible for access dysfunction. After successful angioplasty (≤30% residua

SUBMITTER: Trerotola SO 

PROVIDER: S-EPMC6086699 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature